美国各州关于伊维菌素立法变化及药店销售趋势分析,2020-2026
Changes in the scope and intent of US state legislation on ivermectin and pharmacy dispensing trends, 2020–2026
自2020年起,美国各州关于伊维菌素的立法数量和范围显著增加,从主要针对超说明书使用转变为关注非处方药访问。研究分析了2020年1月至2026年9月期间提出的129项相关法案,并发现疫情期间伊维菌素的药店销售量是疫情前的3.84倍,疫情后仍保持较高水平。这些立法趋势可能对患者安全产生影响。
- Jessica C. Ibiebele ORCID: orcid.org/0000-0002-8032-15701 na1,
- Danielle Parchure2 na1,
- Tianci Chen2,
- Veronika J. Wirtz1,2,
- Kayoko Shioda1,2 na2 &
- …
- Nahid Bhadelia1,3 na2
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
State legislation related to ivermectin use has grown in volume and scope since 2020, despite limited evidence for its effectiveness in treating COVID-19. Media reports suggest that public interest in ivermectin continued after the pandemic and has expanded to other indications alongside promotion by social media influencers and podcasters. In this study, we analyzed ivermectin-related bills introduced from January 2020 to September 2026 and assessed their association with ivermectin dispensing trends. We identified 35 states that introduced 129 ivermectin-related bills, with eight enacting legislation. Legislative focus evolved from predominantly off-label use in 2020–2022 to over-the-counter access in 2025–2026. Early legislation specifically mentioned COVID-19 treatment, while later bills omitted specific medical indications. A sub-analysis using Poisson regression to evaluate the association between state-level ivermectin dispensing rates from 2019 to 2023 and legislative trends identified that dispensed ivermectin quantity per 100,000 population was 3.84 (95% confidence interval [CI] 2.96–4.98) times higher during the pandemic and 1.33 (95% CI 1.23–1.43) times higher post-pandemic compared with the pre-pandemic period, regardless of whether states introduced ivermectin-related legislation. Legislative efforts to bypass federal drug regulation and medical oversight for ivermectin access represent a notable trend with potential implications for patient safety.
Acknowledgements
None.
Author information
Author notes
Jessica C. Ibiebele and Danielle Parchure contributed equally to this work.
Co-last authors: Kayoko Shioda and Nahid Bhadelia
Authors and Affiliations
Boston University Center on Emerging Infectious Diseases, 111 Cummington Mall, Suite 140, Boston, MA, 02125, USA
Jessica C. Ibiebele, Veronika J. Wirtz, Kayoko Shioda & Nahid Bhadelia
Boston University School of Public Health, Boston, MA, USA
Danielle Parchure, Tianci Chen, Veronika J. Wirtz & Kayoko Shioda
Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA
Nahid Bhadelia
Authors
- Jessica C. Ibiebele
- Danielle Parchure
- Tianci Chen
- Veronika J. Wirtz
- Kayoko Shioda
- Nahid Bhadelia
Corresponding author
Correspondence to Jessica C. Ibiebele.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Ibiebele, J.C., Parchure, D., Chen, T. et al. Changes in the scope and intent of US state legislation on ivermectin and pharmacy dispensing trends, 2020–2026. Sci Rep (2026). https://doi.org/10.1038/s41598-026-79482-2
Received: 06 July 2026
Accepted: 31 October 2026
Published: 05 November 2026
DOI: https://doi.org/10.1038/s41598-026-79482-2
Keywords
来源:Nature 健康护理主题 · nature.com